

Members Obtain Free CE Credits from JCP Articles!



Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

December 2018 – *The Journal of Clinical Pharmacology (JCP)*

Why is this article important to you?

Learners that complete this course will be able to summarize the pharmacokinetic and pharmacodynamic properties of nilotinib, a second-generation tyrosine kinase inhibitor, including its drug-drug and food-drug interactions, exposure-efficacy and exposure-safety relationships when used in the treatment of newly diagnosed chronic myeloid leukemia (CML) or accelerated phase CML resistant or intolerant to prior therapy. Clinicians will be able to describe how the PK and PD profiles of nilotinib inform tailoring of treatment to individual patients.



ACPE Accreditation Statement

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

UAN: 0238-0000-18-042-H01-P – ACPE 1 Contact Hours

Activity Type: Knowledge-based **Format:** Home-study **Target Audience:** 'P'



ACCME
ACCREDITED

ACCME Accreditation Statement

The American College of Clinical Pharmacology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME Designation Statement

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1TM* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

Interprofessional team of Physicians, Pharmacists, PhDs, Nurse Practitioners and Physician Assistants.

Learning Objectives

After completing this activity, the learner will be able to:

1. Identify nilotinib-eligible oncology conditions including individualized dosage adjustments based upon patient-specific conditions;
2. Verbalize the rationale and importance of adhering to nilotinib administration 2 hours before or 1 hour after food to achieve predictable drug serum concentrations;
3. Discuss the exposure-safety of nilotinib on QT prolongation and implications for dosing, monitoring and avoidance of concomitant use of QT-prolonging drugs;
4. Identify the impact of gastric pH on the absorption of nilotinib and how to minimize the impact of gastric acid neutralizing agents.

Requirements to Receive Credit

In order to receive CE credit, the learner must register for the educational activity, study the provided journal article, complete the online Self-assessment Post-test, evaluation and certificate. Credits and

certificates must be claimed within 30-days of completing the article, Post-test and evaluation. Contact CE@ACCP1.org with any questions.

Disclosures:

Article Selection: Joseph Bertino, PharmD, FCP, FCCP, Editor-in-Chief, JCP and Owner, Bertino Consulting Inc, selected the article for this course and has nothing to disclose.
Planner: Sandeep Kaushal, MBBS, MD, FCP, Professor & Head of Pharmacology, Dayanand Medical Coll & Hospital, planned the continuing education documentation for this course and has nothing to disclose.
CE Reviewer: Hisham Qosa, PhD, Clinical Pharmacologist, US Food & Drug Admin, Office of Clinical Pharmacology – Division V, has nothing to disclose.

Schedule & Fees

JCP monthly Journal CE articles are generally released on the 1st or 2nd Tuesday of each month. They are priced in packages of Jan - Dec for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

Acknowledgement of Financial Support

No financial support was received for this educational activity.

Home Study Initial Release and Expiration Dates

Date of Issuance: 11/22/2018

Expiration Date: 12/31/2020

Online Location:

https://accp1.org/Members/Continuing_Education/Journal_CE/ACCP1/4Continuing_Education/Journal_CE.aspx

Online Location: How to Print CE Certificates

<https://accp1.org/documents/CommPartners/ReprintCECertificates.pdf>